EE247 Budget Impact of Infliximab Subcutaneous from the US Healthcare Perspective

Abstract

Authors

H Yoo M Jang T Kwon

Full Text Cite This Article
Back to Volume 27, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×